J. Schweizer

发表

Telemedical Support in Patients with Chronic Heart Failure: Experience from Different Projects in Germany

Claudia Sprenger, Thomas M. Helms, T. Helms, 2010, International journal of telemedicine and applications.

Telecardiology Tools and Devices

T. Helms, A. Müller, J. Schwab, 2015, TeleMedicine and Electronic Medicine.

Comparison of tissue plasminogen activator and urokinase in the local infiltration thrombolysis of peripheral arterial occlusions.

R. Kaulén, J. Schweizer, H. Florek, 1996, European journal of radiology.

Potential Use of a Low-Molecular-Weight Heparin to Prevent Restenosis in Patients with Extensive Wall Damage Following Peripheral Angioplasty

W. Kirch, J. Schweizer, A. Müller, 2001, Angiology.

Use of Abciximab and Tirofiban in Patients with Peripheral Arterial Occlusive Disease and Arterial Thrombosis

W. Kirch, J. Schweizer, A. Müller, 2003, Angiology.

Beta-blockers and nitrates in patients with peripheral arterial occlusive disease: long-term findings.

R. Kaulén, J. Schweizer, E. Altmann, 1997, VASA. Zeitschrift fur Gefasskrankheiten.

Short- and Long-Term Results of Abciximab Versus Aspirin in Conjunction with Thrombolysis for Patients with Peripheral Occlusive Arterial Disease and Arterial Thrombosis

W. Kirch, J. Schweizer, A. Müller, 2000, Angiology.

Comparative results of thrombolysis treatment with rt-PA and urokinase: a pilot study.

J. Schweizer, E. Altmann, L. Forkmann, 1998, VASA. Zeitschrift fur Gefasskrankheiten.

[Early complications after acute cerebrovascular insufficiency].

P. K. Schmidt, J. Schweizer, E. Altmann, 1991, Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete.

Comparison of angiotensin II receptor antagonists

W. Kirch, J. Schweizer, B. Horn, 2001, European journal of clinical investigation.

The case for an individualised management strategy

M. Koch, J. Schweizer, A. Schröder, 2002 .

Short- and long-term results after thrombolytic treatment of deep venous thrombosis.

W. Kirch, R. Koch, J. Schweizer, 2000, Journal of the American College of Cardiology.

Candesartan Treatment for Peripheral Occlusive Arterial Disease after Stent Angioplasty

W. Kirch, J. Schweizer, C. Schindler, 2005, Clinical drug investigation.

Deep Venous Thrombosis Short-and Long-Term Results After Thrombolytic Treatment of Deep Venous Thrombosis

W. Kirch, R. Koch, J. Schweizer, 2016 .

Efficacy and safety of valsartan 160/HCTZ 25 mg in fixed combination in hypertensive patients not controlled by candesartan 32 mg plus HCTZ 25 mg in free combination*

J. Schweizer, S. Klebs, R. Handrock, 2007, Current medical research and opinion.

Comparison of Selective AT1-Receptor Blockade Versus ACE Inhibition for Restenosis Prophylaxis in Patients With Peripheral Occlusive Arterial Disease After Stent Angioplasty: A Randomized, Controlled, Proof-of-Concept Study

W. Kirch, P. Bramlage, J. Schweizer, 2007, Angiology.

Efficacy and tolerability of aliskiren 300 mg/hydrochlorothiazide 25 mg (±amlodipine 5 mg) in hypertensive patients not controlled by candesartan 32 mg plus HCT 25 mg

J. Schweizer, S. Klebs, H. Ulmer, 2011, Current medical research and opinion.

Comparison of Two Dosages of Ginkgo biloba Extract EGb 761 in Patients with Peripheral Arterial Occlusive Disease Fontaine’s Stage IIb

J. Schweizer, Christian Hautmann, 1999, Arzneimittelforschung.

Effect of high dose verapamil on restenosis after peripheral angioplasty.

W. Kirch, J. Schweizer, G. Hellner, 1998, Journal of the American College of Cardiology.

130. Comparison of tissue plasminogen activator and urokinase in the local infiltration thrombolysis of peripheral arterial occlusions

R. Kaulén, J. Schweizer, E. Altmann, 1996 .

[Current status of antihypertensive drug treatment in primary care practice at launch of the new renin inhibitor aliskiren (RASANT)].

W. Kirch, A. Müller, J. Schweizer, 2010, Medizinische Klinik.